The head of a major federal drug policy agency acknowledged on Tuesday that the Schedule I status of marijuana and other drugs makes it “very difficult” for researchers to study the benefits and risks of those substances. Nora Volkow, director of the National Institute on Drug Abuse (NIDA), was asked how research would be impacted … Continue reading Top Federal Drug Policy Expert Says Marijuana’s Schedule I Status Inhibits Research